Business Context and Reporting Period
Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed Form 6-K for the month of June 2025. The filing, dated June 12, 2025, serves to report two announcements made to the Australian Securities Exchange (ASX): an "Application for quotation of securities - RAD" and a "Notice Under Section 708A."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding regulatory notices and securities quotation applications rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document. The filing focuses on corporate governance and regulatory compliance actions taken on June 12, 2025.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, or specific risk factors. It includes a standard disclaimer stating that the report and its exhibits shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the status of the "Application for quotation of securities - RAD" referenced in Exhibit 99.1.
- Review the specific details of the "Notice Under Section 708A" provided in Exhibit 99.2.
- Confirm the company's listing status on the Australian Securities Exchange following these announcements.
- Note that this filing does not contain audited or unaudited financial statements.